July 8, 2013 1:42 PM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published on Monday, Piper Jaffray analyst Edward A. Tenthoff reiterated an Overweight rating and a $3 price target on
Novavax (NASDAQ: NVAX). In the report, Piper Jaffray stated, "This morning, Novavax began enrollment of a Phase I study of its monovalent virus- like particle (VLP) vaccine candidate for H7N9 avian flu. Remarkably, Novavax moved into Phase I studies in only 3 months since the H7N9 gene sequence was identified, demonstrating the speed with which Novavax can discover its VLP vaccine candidates. Similarly, Novavax rapidly developed a vaccine candidate against the MERS-CoV Coronavirus, both of which could be procured in case of a pandemic emergency. This alacrity is one of the reasons Novavax was awarded a $97 million BARDA contract to develop pandemic and seasonal flu vaccines." Novavax closed on Friday at $2.62.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.